Table 3.
CMT at each study time point in patients switched directly (Group A) or indirectly (Group B) from anti-VEGF therapy to FAc implant
| CMT at each study time point, µm | Group A | Group B | ||||
|---|---|---|---|---|---|---|
| 12-month cohort (n = 24) |
24-month cohort (n = 17) |
36-month cohort (n = 12) |
12-month cohort (n = 25) |
24-month cohort (n = 15) |
36-month cohort (n = 7) |
|
| Before anti-VEGF | 546.8 (192.0) | 517.4 (177.4) | 490.8 (161.9) | 550.9 (74.8) | 521.8 (70.0) | 497.0 (68.3) |
|
After anti-VEGF P value versus pre-VEGF |
442.5 (172.8) 0.01 |
424.0 (191.8) 0.076 |
417.2 (179.8) 0.119 |
485.4 (165.4) 0.074 |
494.2 (186.5) 0.604 |
639.3 (151.7) 0.015 |
| Before DEX | – | – | – | 584.7 (110.8) | 563.7 (119.5) | 579.3 (154.6) |
|
2 months after DEX P value versus pre-anti-VEGF |
– | – | – |
308.1 (83.9) < 0.001 |
304.3 (81.2) < 0.001 |
277.1 (91.9 < 0.001 |
|
4 months after DEX P value versus pre-anti-VEGF |
– | – | – |
495.5 (163.1) 0.069 |
455.1 (158.6) 0.069 |
437.1 (207.3) 0.31 |
| Before FAc | 603.4 (166.6) | 600 (167.8) | 582.7 (184.1) | 569.6 (127.0) | 540.1 (110.0) | 550.6 (138.0) |
|
3 months after FAc P value versus pre-FAc |
374.3 (144.9) < 0.001 |
352.3 (145.3) < 0.001 |
323.7 (103.3) < 0.001 |
402.0 (138.2) < 0.001 |
357.2 (119.4) < 0.001 |
318.0 (115.6) < 0.001 |
|
6 months after FAc P value versus pre-FAc |
380.6 (154.9) < 0.001 |
355.0 (160.6) < 0.001 |
321.8 (142.6) < 0.001 |
402.9 (149.8) < 0.001 |
358.3 (121.5) < 0.001 |
330.9 (137.9) < 0.001 |
|
9 months after FAc P value versus pre-FAc |
372.0 (144.0) < 0.001 |
336.1 (122.1) < 0.001 |
309.3 (101.3) < 0.001 |
381.1 (178.1) < 0.001 |
325.6 (143.1) < 0.001 |
244.7 (71.4) < 0.001 |
|
12 months after FAc P value versus pre-FAc |
371.6 (143.1) < 0.001 |
359.4 (146.5) < 0.001 |
360.6 (165.6) < 0.001 |
381.0 (179.1) < 0.001 |
330.9 (130.1) < 0.001 |
281.3 (96.1) < 0.001 |
|
18 months after FAc P value versus pre-FAc |
– – |
365.9 (165.3) < 0.001 |
336.1 (134.1) < 0.001 |
– – |
329.2 (113.8) < 0.001 |
298.4 (125.1) < 0.001 |
|
24 months after FAc P value versus pre-FAc |
– – |
379.5 (173.4) < 0.001 |
336.1 (130.3) < 0.001 |
– – |
328.4 (139.8) < 0.001 |
297.7 (151.1) < 0.001 |
|
30 months after FAc P value versus pre-FAc |
– – |
– – |
345.3 (153.8) < 0.001 |
– – |
– – |
243.2 (64.1) < 0.001 |
|
36 months after FAc P value versus pre-FAc |
– – |
– – |
325.1 (147.0) < 0.001 |
– – |
– – |
304.7 (136.1) < 0.001 |
All values are mean (SD). Significant values are shown in bold
CMT central macular thickness, DEX dexamethasone. FAc fluocinolone acetonide, VEGF vascular endothelial growth factor